Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 11 | 2022 | 218 | 1.930 |
Why?
|
| Vaccination | 17 | 2023 | 685 | 1.230 |
Why?
|
| Whooping Cough | 4 | 2022 | 65 | 1.040 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 3 | 2022 | 88 | 0.970 |
Why?
|
| Diphtheria | 2 | 2022 | 13 | 0.880 |
Why?
|
| Tetanus | 2 | 2022 | 17 | 0.870 |
Why?
|
| Humans | 45 | 2023 | 17376 | 0.790 |
Why?
|
| Cataplexy | 1 | 2022 | 6 | 0.770 |
Why?
|
| Narcolepsy | 1 | 2022 | 9 | 0.770 |
Why?
|
| Bell Palsy | 1 | 2022 | 14 | 0.770 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 15 | 0.760 |
Why?
|
| Retrospective Studies | 17 | 2022 | 2428 | 0.720 |
Why?
|
| Myocardial Infarction | 4 | 2022 | 225 | 0.620 |
Why?
|
| Asthma | 3 | 2020 | 388 | 0.550 |
Why?
|
| Cohort Studies | 10 | 2022 | 2526 | 0.540 |
Why?
|
| Blood Cells | 1 | 2016 | 4 | 0.530 |
Why?
|
| Eosinophils | 1 | 2016 | 9 | 0.520 |
Why?
|
| Adult | 20 | 2023 | 7529 | 0.520 |
Why?
|
| Infant | 10 | 2022 | 1162 | 0.510 |
Why?
|
| Female | 26 | 2022 | 12444 | 0.500 |
Why?
|
| Male | 23 | 2022 | 9843 | 0.450 |
Why?
|
| Herpes Zoster Vaccine | 3 | 2021 | 59 | 0.440 |
Why?
|
| Seizures, Febrile | 4 | 2022 | 42 | 0.430 |
Why?
|
| Hospitalization | 7 | 2022 | 805 | 0.400 |
Why?
|
| Pandemics | 4 | 2022 | 285 | 0.390 |
Why?
|
| Aged | 17 | 2021 | 6129 | 0.380 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2021 | 537 | 0.360 |
Why?
|
| Middle Aged | 17 | 2021 | 7885 | 0.350 |
Why?
|
| United States | 13 | 2022 | 3891 | 0.350 |
Why?
|
| Influenza, Human | 3 | 2022 | 282 | 0.350 |
Why?
|
| Adolescent | 12 | 2023 | 3533 | 0.340 |
Why?
|
| Natural Language Processing | 3 | 2022 | 60 | 0.340 |
Why?
|
| Stroke | 3 | 2022 | 310 | 0.330 |
Why?
|
| Outpatients | 2 | 2021 | 101 | 0.330 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2022 | 380 | 0.330 |
Why?
|
| Herpes Zoster | 2 | 2021 | 82 | 0.300 |
Why?
|
| Hepatitis B Vaccines | 2 | 2020 | 44 | 0.280 |
Why?
|
| Incidence | 5 | 2022 | 1266 | 0.280 |
Why?
|
| Databases, Factual | 3 | 2019 | 306 | 0.260 |
Why?
|
| Case-Control Studies | 4 | 2023 | 1100 | 0.260 |
Why?
|
| Infant, Newborn | 4 | 2022 | 805 | 0.260 |
Why?
|
| Young Adult | 11 | 2021 | 2473 | 0.250 |
Why?
|
| Influenza Vaccines | 4 | 2019 | 294 | 0.250 |
Why?
|
| Measles Vaccine | 2 | 2022 | 17 | 0.230 |
Why?
|
| California | 9 | 2022 | 2317 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2023 | 1229 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2014 | 173 | 0.200 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 2022 | 3 | 0.200 |
Why?
|
| Travel | 1 | 2022 | 10 | 0.200 |
Why?
|
| Corynebacterium | 1 | 2022 | 3 | 0.200 |
Why?
|
| Latent Tuberculosis | 1 | 2022 | 11 | 0.200 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 1942 | 0.200 |
Why?
|
| Shoulder Injuries | 1 | 2022 | 2 | 0.200 |
Why?
|
| Placenta | 1 | 2022 | 20 | 0.190 |
Why?
|
| Tuberculosis | 1 | 2022 | 24 | 0.190 |
Why?
|
| Orthopedic Procedures | 1 | 2022 | 6 | 0.190 |
Why?
|
| Anaphylaxis | 2 | 2019 | 16 | 0.190 |
Why?
|
| Child, Preschool | 8 | 2021 | 1375 | 0.190 |
Why?
|
| Measles | 1 | 2022 | 24 | 0.190 |
Why?
|
| Child | 8 | 2022 | 2382 | 0.180 |
Why?
|
| Politics | 1 | 2020 | 10 | 0.170 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 12 | 0.170 |
Why?
|
| Inpatients | 1 | 2021 | 79 | 0.170 |
Why?
|
| Vaccination Coverage | 1 | 2021 | 52 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 19 | 0.170 |
Why?
|
| Diabetes Complications | 1 | 2021 | 106 | 0.170 |
Why?
|
| Hepatitis B | 1 | 2020 | 45 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.170 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 381 | 0.160 |
Why?
|
| Ischemia | 1 | 2019 | 4 | 0.160 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 12 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 395 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.160 |
Why?
|
| Hypertension | 2 | 2020 | 469 | 0.160 |
Why?
|
| Autism Spectrum Disorder | 1 | 2022 | 159 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2020 | 133 | 0.160 |
Why?
|
| Pregnancy | 2 | 2022 | 1466 | 0.160 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 155 | 0.160 |
Why?
|
| Recurrence | 2 | 2016 | 165 | 0.160 |
Why?
|
| Risk | 3 | 2020 | 498 | 0.150 |
Why?
|
| Dyslipidemias | 1 | 2019 | 56 | 0.150 |
Why?
|
| Pain | 1 | 2019 | 75 | 0.150 |
Why?
|
| Disease Progression | 2 | 2016 | 259 | 0.150 |
Why?
|
| Telemedicine | 1 | 2021 | 182 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 205 | 0.140 |
Why?
|
| Medicare Part D | 1 | 2017 | 15 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 165 | 0.140 |
Why?
|
| Cost Sharing | 1 | 2017 | 29 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1170 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 311 | 0.130 |
Why?
|
| Cell Count | 1 | 2016 | 11 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 533 | 0.130 |
Why?
|
| Heart Failure | 1 | 2022 | 404 | 0.130 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2016 | 54 | 0.130 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.130 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 86 | 0.130 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 6 | 0.120 |
Why?
|
| Biomarkers | 1 | 2016 | 306 | 0.120 |
Why?
|
| Immunization Schedule | 3 | 2021 | 124 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 158 | 0.120 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.120 |
Why?
|
| Premature Birth | 1 | 2016 | 132 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 151 | 0.110 |
Why?
|
| Algorithms | 3 | 2022 | 226 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 666 | 0.110 |
Why?
|
| Obesity | 1 | 2020 | 814 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2014 | 81 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2014 | 66 | 0.110 |
Why?
|
| Risk Factors | 5 | 2020 | 3255 | 0.110 |
Why?
|
| Biometry | 1 | 2014 | 14 | 0.110 |
Why?
|
| Safety | 1 | 2014 | 43 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2015 | 211 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 1155 | 0.100 |
Why?
|
| Time Factors | 4 | 2019 | 1044 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 114 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 102 | 0.100 |
Why?
|
| HIV Infections | 1 | 2019 | 712 | 0.100 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 68 | 0.100 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 93 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 109 | 0.090 |
Why?
|
| Age Factors | 3 | 2020 | 884 | 0.090 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 80 | 0.080 |
Why?
|
| Fever | 2 | 2022 | 54 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 47 | 0.070 |
Why?
|
| Sex Factors | 2 | 2020 | 607 | 0.070 |
Why?
|
| Immunization Programs | 2 | 2020 | 65 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 564 | 0.070 |
Why?
|
| Vaccines, Inactivated | 2 | 2019 | 72 | 0.060 |
Why?
|
| Prevalence | 2 | 2021 | 839 | 0.060 |
Why?
|
| Maternal Age | 2 | 2016 | 74 | 0.060 |
Why?
|
| Managed Care Programs | 2 | 2017 | 309 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2016 | 96 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2019 | 707 | 0.050 |
Why?
|
| Travel-Related Illness | 1 | 2022 | 3 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2023 | 72 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 36 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 144 | 0.050 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2022 | 62 | 0.050 |
Why?
|
| Aftercare | 1 | 2022 | 48 | 0.050 |
Why?
|
| Chickenpox Vaccine | 1 | 2022 | 91 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 16 | 0.040 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 9 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 36 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 107 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 44 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 84 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 154 | 0.040 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 31 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2020 | 275 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 122 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 2019 | 44 | 0.040 |
Why?
|
| Critical Illness | 1 | 2019 | 51 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 144 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 135 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 228 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2019 | 152 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 439 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 311 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 29 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 13 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2016 | 56 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 455 | 0.030 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.030 |
Why?
|
| Bias | 1 | 2016 | 100 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 937 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 82 | 0.030 |
Why?
|
| Seasons | 1 | 2016 | 113 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 86 | 0.030 |
Why?
|
| Epilepsy | 1 | 2014 | 13 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 45 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 85 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 165 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 280 | 0.030 |
Why?
|
| Gestational Age | 1 | 2014 | 112 | 0.030 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2013 | 15 | 0.030 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2013 | 18 | 0.030 |
Why?
|
| Vaccines, Acellular | 1 | 2012 | 11 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2013 | 59 | 0.030 |
Why?
|
| Quality Control | 1 | 2012 | 42 | 0.030 |
Why?
|
| Off-Label Use | 1 | 2012 | 14 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 538 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 644 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 702 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 1079 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2014 | 456 | 0.020 |
Why?
|
Concepts
(187)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(31)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->